Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?

PURPOSE: Ovarian cancer is the most lethal gynaecological malignancy. Despite the introduction of bevacizumab, standard chemotherapy has remained largely unchanged and the vast majority of patients will relapse within the first two years of diagnosis. However, results from recent clinical trials dem...

Descripción completa

Detalles Bibliográficos
Autores principales: Klotz, Daniel Martin, Wimberger, Pauline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524817/
https://www.ncbi.nlm.nih.gov/pubmed/32833070
http://dx.doi.org/10.1007/s00404-020-05677-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524817/
https://www.ncbi.nlm.nih.gov/pubmed/32833070
http://dx.doi.org/10.1007/s00404-020-05677-1

Ejemplares similares